Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Placebo-Controlled Study of E5564, A Lipid A Antagonist, Administered by Twice Daily Infusions in Patients With Severe Sepsis

NCT00046072 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT00046072
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00046072 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Placebo-Controlled Study of E5564, A Lipid A Antagonist, Administered by Twice Daily Infusions in Patients With Severe Sepsis
Lead sponsor
Eisai Inc.
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2001
Completion date
April 30, 2005
Enrollment
300
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

infection, sepsis, sepsis syndrome, septicemia, shock, septic